O R I G I N a L I N V E S T I G a T I O N Open Access

Associations between retinol-binding protein 4 and cardiometabolic risk factors and subclinical atherosclerosis in recently postmenopausal women: cross-sectional analyses from the KEEPS study Abstract Background: The published literature regarding the relationships between retinol-binding protein 4 (RBP4) and cardiometabolic risk factors and subclinical atherosclerosis is conflicting, likely due, in part, to limitations of frequently used RBP4 assays. Prior large studies have not utilized the gold-standard western blot analysis of RBP4 levels.

[1]  S. Mallat.  What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment? , 2012, Cardiovascular Diabetology.

[2]  C. Eaton,et al.  Implications of New Hypertension Guidelines in the United States , 2011, Hypertension.

[3]  A. Gradman.  Rationale for Triple‐Combination Therapy for Management of High Blood Pressure , 2010, Journal of clinical hypertension.

[4]  William Chen,et al.  Antihypertensive medication adherence and subsequent healthcare utilization and costs. , 2010, The American journal of managed care.

[5]  C. Ker,et al.  Decreased retinol binding protein 4 concentrations are associated with cholesterol gallstone disease. , 2010, Journal of the Formosan Medical Association = Taiwan yi zhi.

[6]  E. Ingelsson,et al.  Circulating Retinol-Binding Protein 4 and Subclinical Cardiovascular Disease in the Elderly , 2008, Diabetes Care.

[7]  R. Nelson,et al.  Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations* , 2008, Current medical research and opinion.

[8]  P. Kowey,et al.  Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. , 2008, American heart journal.

[9]  M. Górska,et al.  Serum retinol binding protein 4 is related to insulin resistance and nonoxidative glucose metabolism in lean and obese women with normal glucose tolerance. , 2008, The Journal of clinical endocrinology and metabolism.

[10]  P. Lepper,et al.  Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease , 2007, Diabetologia.

[11]  Arya M. Sharma,et al.  Retinol-Binding Protein 4 in Human Obesity , 2006, Diabetes.

[12]  B. Staels.  Regulation of lipid and lipoprotein metabolism by retinoids. , 2001, Journal of the American Academy of Dermatology.

[13]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[14]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[15]  R. Detrano,et al.  Quantification of coronary artery calcium using ultrafast computed tomography. , 1990, Journal of the American College of Cardiology.

[16]  Michael E. Miller,et al.  Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes , 2011 .